Colony-stimulating factors for febrile neutropenia during cancer therapy.
about
New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastimBiosimilars in the management of neutropenia: focus on filgrastimAntineoplastic agents and the associated myelosuppressive effects: a review.Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: A single center, retrospective analysis of blood stream infectionInfection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma.Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis.A case-control study to identify risk factors for totally implantable central venous port-related bloodstream infection.Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community OncologyIncidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.Management of Acute Myeloid Leukemia in the Intensive Care Setting.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.rhCSF3 accelerates the proliferation of human melanocytes in culture through binding CSF3R and the expression of CSF3R transcripts.Tumor Microenvironment and Differential Responses to Therapy.Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question.Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.Evaluation of Filgrastim Therapy in Kidney Transplant Recipients.Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.Atrial natriuretic peptide protects against cisplatin-induced granulocytopenia.Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers.Management and Preventive Measures for Febrile Neutropenia.Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
P2860
Q26738509-0A72B489-AFA3-4CD6-BFB0-8D2B1D5B06E9Q26764906-D3C6A8C2-CE31-4579-8880-5D5B5549AEE8Q33417225-719F0DF3-7AE0-4C4A-B536-50F4B8E275CDQ33708035-D10B5F28-67D3-407E-B6E9-99CF479A6B4DQ33861071-4037EF18-B99C-44CD-956B-3D1015F8EA86Q33993410-F4D6F26C-208B-4512-94AB-9D996240B085Q34043439-97C5DB85-6A93-444D-A719-20214F467C3AQ34106812-620B17C8-F2B0-496E-9F52-64B547153CFDQ34670717-273FDAA3-6616-45F8-9951-82328E411F3EQ34982532-4337E903-1D5D-4CFF-A3A4-EB6FB06EC95BQ36007020-554B5E2B-9EE1-4490-88BE-2918A3593E8BQ36026000-3F4B4FD2-EB2A-40FB-A196-E488CA4E1612Q36769011-AE332134-9C86-4A4F-8115-D564DC650877Q37717738-D39C21AD-0F0D-4F80-BD6E-7BE2C9B7DF60Q38206394-E20888F3-950B-45AB-BE66-236802E29593Q38225700-E4C96284-D1CF-4048-9DFF-4E1CA5B4B92AQ38613025-20C35727-E9E7-4507-88A4-5C7BC1EA4B67Q38911337-67D08B57-1F5B-472D-A17A-D9BE6E321970Q39141484-EA89C562-7869-4604-95F5-7B540E75C927Q40077907-F19D7EE6-8DAD-45CF-946F-AB8344312BABQ40150202-3B30C811-C929-43BE-A08A-2CF97B552431Q40402240-768151C7-A262-4CBB-828E-22B8B5CBEE72Q40810746-B04C763C-6F4D-4467-B0D3-4311BBFC20CEQ40829486-54B2A4F1-2619-455A-8002-6FF69165C9AEQ41928773-05D0797B-8C64-45A1-A19D-B9E03F232ED8Q41956513-5FA3A6C1-9F9D-4179-B56E-476345645433Q41958401-DFD5E241-D27B-457B-BF02-74D2B7E3E8A3Q42540897-73E04920-3124-4121-8FEF-AE30CBA74B0AQ45746480-1E6326A7-60B6-461E-9A73-F8E0843AB67DQ47396094-B82CB803-6792-44DC-BA83-A60A503B7259Q47657705-C0FEAAC1-4329-4227-ACF7-49A41EC4D89CQ47668200-A5B3513A-A3B9-4C63-9D49-8BCCBCB43256Q48606842-AB8167F6-A992-4D2E-A2E4-97ED96B5C10AQ50237854-6A380D19-D97B-4262-AF03-F401C0A099E2Q50584736-D0D200F3-4659-4BB4-843D-EFEF3EBF6AA5Q51712236-34CC7478-1214-445A-A418-6E5781667180Q53137786-78366BF0-FCB6-4D7F-8FB5-7E9384BBAFC3Q54945637-2F0E4AA3-5643-4151-87AD-6A899A9417ECQ58767839-007E97AF-67D7-4446-8CA2-A01D4544BA68
P2860
Colony-stimulating factors for febrile neutropenia during cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@en
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@nl
type
label
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@en
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@nl
prefLabel
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@en
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@nl
P2860
P356
P1476
Colony-stimulating factors for febrile neutropenia during cancer therapy.
@en
P2093
Charles L Bennett
LeAnn B Norris
P2860
P304
P356
10.1056/NEJMCT1210890
P407
P577
2013-03-01T00:00:00Z